Vir Biotechnology vs Xencor
VIR and XNCR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How VIR and XNCR compare
Xencor is the larger company, worth 1.6 times as much as Vir Biotechnology ($2.8B against $1.7B).
Vir Biotechnology grew revenue faster over the last twelve months (1696% versus 33.5% for Xencor).
Xencor keeps more of each dollar of sales as profit, with a net margin of −58.8% compared with −61.0% at Vir Biotechnology.
Vir Biotechnology scores higher on the StockData Score (12 against 7 for Xencor), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | VIR | XNCR |
|---|---|---|
| Size and price | ||
| Market cap | $1.7B | $2.8B |
| Share price | $9.96 | $37.09 |
| Change, 1 year | 74.4% | 158% |
| Change, 5 years | −69.6% | 0.62% |
| Beta (5Y) | 0.72 | 1.03 |
| Employees | 367 | 260 |
| StockData Score | ||
| Total score | 12 (better) | 7 |
| Valuation score | 3 (better) | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 2 | 2 |
| Health score | 6 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 5.6× (better) | 13.8× |
| P/B | 1.9× (better) | 4.9× |
| FCF yield | −8.4% | −6.4% (better) |
| Fair value | $12.60 | $16.35 |
| Margin of safety | 21.0% (better) | −127% |
| Growth | ||
| Revenue growth (TTM) | 1696% (better) | 33.5% |
| Revenue growth, 5Y average | −2.1% | 0.47% (better) |
| Profitability | ||
| Operating margin | −69.8% (better) | −72.7% |
| Net margin | −61.0% | −58.8% (better) |
| FCF margin | −46.8% (better) | −88.0% |
| Return on equity | −21.8% | −19.9% (better) |
| Return on invested capital | −45.2% | −17.4% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.17 (better) |
| Interest coverage | – | −6.2× |
| Current ratio | 6.30 | 6.54 (better) |
| Altman Z-score | 3.11 | 6.52 (better) |
| Piotroski F-score | 3 | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 86.6% | 113% |
| Held by insiders | 17.0% | 1.6% |
| Insider net buying, 12 months | −$4.0M (better) | −$7.5M |
| Short interest, % of float | 12.0% | 17.6% |
Go deeper
- VIR stock overview
- VIR income statement
- VIR valuation and score
- XNCR stock overview
- XNCR income statement
- XNCR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.